granted accelerated approval to Balversa erdafitinib for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations that has progressed during or following platinum-containing chemotherapy includi [...]
Women who are not at high risk for breast cancer can wait to start getting mammograms until age 50 and be screened every other year according to new guidelines from the American College of Physicians Women at high risk for breast cancer are those with a f [...]
Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer The analyses was performed by British physicians in the E [...]
A new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients 20 out of 24 as of an interim analysis of the phase 1b trial data The early findings provide hope that this strategy i [...]
An early phase clinical trial evaluating dostarlimab in women with recurrent or advanced endometrial cancer appears promising These data were presented at the 2019 Society for Gynecologic Oncology SGO Annual Meeting on Womens Cancer in Honolulu Hawaii End [...]
The NCCN has recently updated its ovarian cancer treatment guidelines and make the following significant changes All patients with ovarian cancer fallopian tube cancer or primary peritoneal cancer should have a genetic risk evaluation and BRCA12 testing p [...]
PHILADELPHIA PA Prophylactic cranial irradiation PCI a technique used to prevent the clinical development of brain metastases is established as a standard approach for many patients with small cell lung cancer SCLC after initial therapy While studies esta [...]
Lynparza olaparib improves progression-free survival PFS when used to treat BRCA-mutated pancreatic cancer and appears to represent a new treatment option for this hard to treat cancer 1-4 About BRCA Mutated Pancreatic Cancer Pancreatic cancer has the wor [...]
Results of the phase III ARAMIS clinical trial were published in The New England Journal of Medicine and demonstrated that Darolutamide plus androgen deprivation therapy ADT significantly extends metastasis-free survival compared to placebo plus ADT in no [...]
The US Food and Drug Administration FDA has approved IMBRUVICA ibrutinib in combination with Gazyva obinutuzumab for treatments of patients with chronic lymphocytic leukemiasmall lymphocytic lymphoma CLLSLL 1 The FDA approval was based on results from the [...]
